Handelsbanken Fonder AB Increases Stake in Glaukos Co. (NYSE:GKOS)

Handelsbanken Fonder AB increased its holdings in shares of Glaukos Co. (NYSE:GKOS) by 0.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,700 shares of the medical instruments supplier’s stock after purchasing an additional 100 shares during the quarter. Handelsbanken Fonder AB’s holdings in Glaukos were worth $2,204,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GKOS. CIBC Asset Management Inc acquired a new stake in Glaukos in the fourth quarter valued at approximately $227,000. State of New Jersey Common Pension Fund D grew its position in Glaukos by 2.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 19,883 shares of the medical instruments supplier’s stock valued at $2,981,000 after acquiring an additional 465 shares in the last quarter. Congress Asset Management Co. acquired a new stake in Glaukos in the fourth quarter valued at approximately $219,000. Rhumbline Advisers grew its position in Glaukos by 0.3% in the fourth quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier’s stock valued at $21,260,000 after acquiring an additional 403 shares in the last quarter. Finally, Asset Planning Inc acquired a new stake in Glaukos in the fourth quarter valued at approximately $90,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Stock Down 1.2 %

GKOS opened at $124.34 on Tuesday. The business has a 50 day moving average price of $152.35 and a 200 day moving average price of $139.60. Glaukos Co. has a twelve month low of $83.90 and a twelve month high of $163.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The firm has a market cap of $6.86 billion, a P/E ratio of -43.32 and a beta of 1.04.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The business had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Research analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and increased their price objective for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. Stephens raised shares of Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. Wells Fargo & Company increased their price objective on shares of Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research report on Friday. JPMorgan Chase & Co. raised their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Finally, Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and an average target price of $163.25.

Insider Activity

In other news, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gilbert H. Kliman sold 10,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the sale, the director now owns 32,336 shares of the company’s stock, valued at $4,859,454.08. This represents a 23.62 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,744 shares of company stock worth $2,792,151. Company insiders own 6.40% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.